JONES DAY TALKS®: A Trip to the Dark Side – Venture Capital Down Rounds and Recaps
PODCAST: Williams Mullen's Raising Capital 101: A Securities Podcast - Why Raise Capital?
The Power of Genuine Networking for Entrepreneurs With OneSixOne Ventures with Pablo Casilimas and Justis Mendez
PODCAST: Williams Mullen's Raising Capital 101: A Securities Podcast - The Aspects of Raising Capital from Start-Ups to More Established Companies
A Conversation with Janade du Plessis of Launch Africa Ventures: Balancing Sustainable Development with ROI
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 182: Life Sciences Startups and Leadership with Scott Pancoast of Zylo Therapeutics
Podcast - Open Finance
Our survey analyzed the terms of 171 venture financings closed in the fourth quarter of 2023 by companies headquartered in Silicon Valley. Fourth-quarter Bay Area venture capital financings remained largely flat from the...more
Recorded at SCbio’s 2024 annual conference, Heather and Matthew are joined by Scott Pancoast, the Founder and CEO of Zylo Therapeutics, who also sits on the board of SCbio. Scott has an impressive track record of investing in...more
Third-quarter Bay Area venture capital financings reached the highest number in the past 12 months (188), including the most Series A financings (100) since Q2 2021. However, Q3 was notably consistent with the prior quarter,...more
The challenging funding environment will likely prompt small- and mid-cap listed life sciences companies to seek financing through private investments in public equity. Small- and mid-cap life sciences companies typically...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q1 2023 include: • Life sciences VC deal value totaled $5.0 billion across 364 deals, representing a 40.9% decline in value...more
Following a record-breaking year for initial public offerings (IPOs) in 2021, the U.S. capital markets screeched to a halt in 2022 with the lowest IPO activity levels seen in decades. This trend was observed across all...more
Our survey analyzed the terms of 194 venture financings closed in the second quarter of 2022 by companies headquartered in Silicon Valley. While the number of venture financings were down in the second quarter compared to...more
Our survey analyzed the terms of 287 venture financings closed in the fourth quarter of 2021 by companies headquartered in Silicon Valley. Key Findings - • Valuation results again reached new record highs, with the...more
Our survey analyzed the terms of 260 venture financings closed in the third quarter of 2021 by companies headquartered in Silicon Valley. Key Findings: • Valuation results remain near historical highs with the average...more
This edition of Orrick’s life sciences publication series reviews the key drivers of venture investment in the life sciences industry, which is proceeding at a record pace thus far in 2021. Key findings include: Investment...more
Our latest survey, analyzing the terms of 259 venture financings closed in the first quarter of 2021 by companies headquartered in Silicon Valley, shows valuation results continued their momentum from the fourth quarter of...more
Bigfoot Biomedical®, a Milpitas, CA emerging company, recently announced that it has secured new financing of up to $57 million in combined debt and equity financing from Madryn Asset Management LP, an alternative asset...more
Our survey analyzed the terms of 229 venture financings closed in the fourth quarter of 2020 by companies headquartered in Silicon Valley. Key Findings - Valuation results rebounded from the prior quarter, but remain...more
This survey is a special interim report to highlight changes in the Silicon Valley venture capital environment through October 2020 in light of the COVID-19 pandemic. Please note that when providing data on a monthly...more
Our survey analyzed the terms of 211 venture financings closed in the third quarter of 2020 by companies headquartered in Silicon Valley. Key Findings - Valuation results rebounded from the prior quarter, but remain...more
This survey is a special interim report to highlight changes in the Silicon Valley venture capital environment through August 2020 in light of the COVID-19 pandemic. Please note that when providing data on a monthly basis,...more
This survey is a special interim report to highlight changes in the Silicon Valley venture capital environment through July 2020 in light of the COVID-19 pandemic. Please note that when providing data on a monthly basis,...more
Background - Our survey analyzed the terms of 203 venture financings closed in the second quarter of 2020 by companies headquartered in Silicon Valley. The Q2 2020 survey is the first to analyze a full quarter of results...more
This survey is a special interim report to highlight changes in the Silicon Valley venture capital environment in light of the COVID-19 pandemic. It focuses on May financing activity and supplements our March 2020 and April...more
This survey is a special interim report to highlight changes in the Silicon Valley venture capital environment in light of the COVID-19 pandemic. It focuses on April financing activity and supplements our March Flash Report...more
Following the wider outbreak of the coronavirus (COVID-19) around the world, radical—and sometimes controversial—actions have been and are further expected to be taken by national, federal and local governments and...more
We analyzed the terms of 188 venture financings closed in the fourth quarter of 2019 by companies headquartered in Silicon Valley. The quarter recorded the highest average and median price increases in the 16-year history of...more
We analyzed the terms of 189 venture financings closed in the third quarter of 2019 by companies headquartered in Silicon Valley. The quarter recorded the highest average price increase since mid-2015. The software and...more
We analyzed the terms of 215 venture financings closed in the second quarter of 2019 by companies headquartered in Silicon Valley. The quarter showed the highest percentage of up rounds since 2004, when we first started...more
The Committee on Foreign Investment in the United States recently broadened its coverage of biotechnology transactions via new regulations that became effective on November 10, 2018. This article provides perspectives about...more